Apogee Therapeutics, Inc. (APGE)
| Market Cap | 6.45B +193.2% |
| Revenue (ttm) | n/a |
| Net Income | -274.62M |
| EPS | -4.32 |
| Shares Out | 74.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 709,327 |
| Open | 89.66 |
| Previous Close | 88.33 |
| Day's Range | 85.87 - 90.07 |
| 52-Week Range | 34.34 - 95.32 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 119.50 (+38.87%) |
| Earnings Date | May 11, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price target is $119.5, which is an increase of 38.87% from the latest price.
News
Apogee Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Recent data show zumilokibart delivers robust, durable efficacy in atopic dermatitis with fewer doses, supporting phase III trials and expansion into asthma and EoE. Strategic financing ensures commercialization through 2029, while differentiated dosing and efficacy position the pipeline for strong market access and growth.
Apogee Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation. All proposals passed with sufficient votes, and no shareholder questions were raised.
Apogee Therapeutics price target raised to $97 from $82 at RBC Capital
RBC Capital raised the firm’s price target on Apogee Therapeutics (APGE) to $97 from $82 and keeps a Sector Perform rating on the shares. To gauge the potential future use…
Apogee Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Zumilokibart demonstrated strong phase II-B efficacy in atopic dermatitis, with phase III trials and expansion into asthma and EoE planned. A $1.3 billion Blackstone deal secures funding through commercialization, supporting robust development and strategic flexibility.
Apogee Therapeutics to Participate in Upcoming June Conferences
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics moved to Neutral at Goldman Sachs
Goldman Sachs moved Apogee Therapeutics (APGE) to a Neutral rating from Early Stage Biotech, with a 12-month price target of $89, after the company disclosed 16-week Phase 2 Part B…
Apogee Therapeutics price target lowered to $81 from $83 at Truist
Truist analyst Danielle Brill lowered the firm’s price target on Apogee Therapeutics (APGE) to $81 from $83 and keeps a Hold rating on the shares. The firm’s views on the…
Apogee Therapeutics price target raised to $135 from $120 at Wedbush
Wedbush raised the firm’s price target on Apogee Therapeutics (APGE) to $135 from $120 and keeps an Outperform rating on the shares. The firm notes the company reported APEX Part…
Apogee secures up to $1.3 billion from Blackstone to advance eczema drug
Apogee Therapeutics said on Wednesday it secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support late-stage development and potential commercialization of its exper...
Apogee Therapeutics Transcript: Study result
APEX Part B phase II results show mid-dose zumilokibart achieved strong efficacy (65.9% EASI-75, 46% IGA 0/1, 47.4% EASI-90 at week 16) and a favorable safety profile, with a dramatic reduction in injection burden. Phase III trials and expansion into asthma and EoE are planned.
Apogee Therapeutics Slides: Study result
Apogee Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Apogee Therapeutics Press release: Study result
Apogee Therapeutics issued a press release on May 27, 2026, disclosing material business information to investors.
Apogee Therapeutics announces $1.3B financing pact with Blackstone Life Sciences
Apogee Therapeutics (APGE) announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3B in flexible, non-dilutive total capital...
Apogee Therapeutics reports ‘positive’ results from Part B of Phase 2 APEX trial
Apogee Therapeutics (APGE) announced positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart, a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-s...
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H ...
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best...
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and ...
Apogee Therapeutics Earnings release: Q1 2026
Apogee Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Apogee Therapeutics Quarterly report: Q1 2026
Apogee Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Qize Ding initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $140 price target The firm has a “bullish view” on APG777 into…
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
Mizuho raised the firm’s price target on Apogee Therapeutics (APGE) to $110 from $105 and keeps an Outperform rating on the shares. The firm cites last week’s 52-week data for…
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...